Skip to main content

Table 2 Predictors of persistent anemia after 12 months of ART among 102 HIV-infected adults who were anemic at ART initiation

From: Antiretroviral treatment reverses HIV-associated anemia in rural Tanzania

   

Crudea

Adjustedb

Variables

Total

Anemic after 12 months (%)

OR (95% CI)

P

OR (95% CI)

P

Gender

      

   Female

75

30 (40.0)

1

   

   Male

27

9 (33.3)

0.85 (0.33-2.20)

0.744

  

Age (years)

      

   <30

26

10 (38.5)

1

   

   30-39

42

19 (45.2)

1.45 (0.52-4.01)

0.476

  

   ≥40

34

10 (29.4)

0.77 (0.25-2.33)

0.641

  

AIDSc

      

   No

41

16 (39.0)

1

   

   Yes

61

23 (37.7)

0.93 (0.41-2.13)

0.862

  

Tuberculosisd

      

   No

80

31 (38.8)

1

   

   Yes

22

8 (36.4)

0.69 (0.24-1.94)

0.477

  

BMI (kg/m2)

      

   <16

26

9 (34.6)

1

   

   16-18.4

35

15 (42.9)

1.62 (0.55-4.78)

0.382

  

   ≥18.5

40

14 (35.0)

1.24 (0.42-3.64)

0.702

  

MCV (fL)

      

   ≥87.5

25

6 (24.0)

1

 

1

 

   82.1-87.4

27

9 (33.3)

1.47 (0.43-5.06)

0.538

1.35 (0.38-4.72)

0.644

   76.0-82.0

25

9 (36.0)

1.75 (0.51-6.00)

0.377

1.42 (0.39-5.13)

0.595

   <76.0

25

15 (60.0)

4.05 (1.17-14.1)

0.028

4.34 (1.22-15.5)

0.023

MCH (pg)

      

   ≥28.1

26

7 (26.9)

1

   

   26.6-28.0

24

7 (29.2)

1.14 (0.33-3.95)

0.841

  

   23.8-26.5

26

10 (38.5)

1.70 (0.52-5.52)

0.380

  

   <23.8

26

15 (57.7)

3.20 (0.97-10.5)

0.056

  

Initial regimen

      

   Stavudine

79

27 (34.2)

1

 

1

 

   Zidovudine

23

12 (52.2)

2.46 (0.93-6.54)

0.071

2.91 (1.03-8.19)

0.043

  1. aAdjusted for baseline hemoglobin. bAdjusted for baseline hemoglobin and the other variables listed in the final model. MCH was excluded because of collinearity with MCV. cWorld Health Organization clinical stage 4. dOn tuberculosis treatment at ART initiation or started within the observation period of 12 months.
  2. OR, odds ratio; CI, confidence interval; BMI, body mass index; MCV, mean cell volume; MCH, mean corpuscular hemoglobin.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us